COVID-19 Screening in Rheumatologic Diseases Cases; Special Look at Chloroquine Derivate Use

Hospital Practices and Research

article

Shadmanfar, Soraya¹  Alishiri, Gholamhosein²  Bayat, Noushin³  Izadi, Morteza¹  Salimzadeh, Ahmad⁴  Rostamian, Abdolrahman⁵  Abolghasemi, Shahla⁶  Azimzadeh Ardebili, Mohammad Hossein⁷  Rastgar Moqaddam, Zeynab⁸  Hasani, Marjan⁷  Rahmanian, Ehsan⁷  Iranpanah, Helia⁹  Islami, Ghodrat Allah⁷  Saburi, Amin² 

[1] Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences;Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences;Exercise Physiology Research Center, Life Style Institute, Baqyiatallah University of Medical Sciences;Sina Hospital, Rheumatology Research Center, Tehran University of Medical Sciences;Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences;Department of Rheumatology, Tehran Medical Sciences, Islamic Azad University;Student Research Committee, Baqiyatallah University of Medical Sciences;Iran University of Medical Science;Shahid Beheshti University of Medical Sciences

关键词: Angiotensin-Converting Enzyme Inhibitors;    Angiotensin II Type 1 Receptor Blockers;    Chloroquine;    Hydroxychloroquine;    COVID-19;   

DOI  :  10.34172/hpr.2021.27

学科分类：社会科学、人文和艺术（综合）

来源: Baqiyatallah University of Medical Sciences

【 摘 要 】

Background: Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.Objectives: The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate.Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use.Results: 1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999).Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders.

【 授权许可】

CC BY